Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Author's Avatar
Aug 23, 2022

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced the publication of a peer-reviewed article in %3Ci%3EClinical+%26amp%3B+Translational+Immunology%3C%2Fi%3E characterizing B cell repertoires in tissue samples from patients with breast cancer. In collaboration with groups at the University of Vermont Larner College of Medicine and the University of Pennsylvania, the preclinical study combined next-generation sequence analysis and phage panning to characterize and enrich clonal lineages of tumor-specific B cells in discrete tissues from cancer patients.